Exosomes and cancer - Diagnostic and prognostic biomarkers and therapeutic vehicle

• Published in: Oncogenesis (New York, NY) Vol. 11; no. 1; pp. 54 - 12
• Main Authors: Wang, Xia, Tian, Lu, Lu, Jingyi, Ng, Irene Oi-Lin
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 15.09.2022; Nature Publishing Group
• Subjects: 631/67; 631/67/1857; Apoptosis; Biomarkers; Cancer; Cell Biology; Drug development; Endocytosis; Exosomes; Extracellular vesicles; Human Genetics; Immunosuppressive agents; Internal Medicine; Lipid metabolism; Medicine; Medicine & Public Health; Oncology; Review; Review Article; Therapeutic targets
• ISSN: 2157-9024; 2157-9024
• DOI: 10.1038/s41389-022-00431-5

Exosomes belong to a subpopulation of extracellular vesicles secreted by the dynamic multistep endocytosis process and carry diverse functional molecular cargoes, including proteins, lipids, nucleic acids (DNA, messenger and noncoding RNA), and metabolites to promote intercellular communication. Proteins and noncoding RNA are among the most abundant contents in exosomes; they have biological functions and are selectively packaged into exosomes. Exosomes derived from tumor, stromal and immune cells contribute to the multiple stages of cancer progression as well as resistance to therapy. In this review, we will discuss the biogenesis of exosomes and their roles in cancer development. Since specific contents within exosomes originate from their cells of origin, this property allows exosomes to function as valuable biomarkers. We will also discuss the potential use of exosomes as diagnostic and prognostic biomarkers or predictors for different therapeutic strategies for multiple cancers. Furthermore, the applications of exosomes as direct therapeutic targets or engineered vehicles for drugs are an important field of exosome study. Better understanding of exosome biology may pave the way to promising exosome-based clinical applications.